2023 World Conference on Lung Cancer (Posters)-EP06.06. EBUS as a Novel Procedure for Microbiome Collection and Analysis in NSCLC

EP06.06. EBUS as a Novel Procedure for Microbiome Collection and Analysis in NSCLC - PDF(Abstract)

Pdf Summary

This study aims to demonstrate the feasibility of using the Endobronchial Ultrasound guided biopsy (EBUS) procedure to collect and analyze microbiome samples in patients with non-small cell lung cancer (NSCLC). Previous studies have shown that the human microbiome, specifically the gut, lower respiratory tract, and oral microbiome, plays a role in predicting treatment response and recurrence in NSCLC. The EBUS procedure presents an opportunity to collect microbiome samples effectively. Patients attending a referral center for EBUS were recruited for the study. Bronchoalveolar fluid, oral swabs, and stool samples were collected and stored for future analysis. Preliminary results show that small volume lavage and protected brushings were possible in a high percentage of cases (88% and 76%, respectively). Oral samples were obtained in 93% of cases, while stool samples were only returned by 37% of patients. Of the patients, 59% had advanced NSCLC and 54% received systemic therapy. Recruitment for the study is ongoing, and analysis of the microbiome samples will be conducted as the database expands. The findings from this study could potentially contribute to personalized treatment choices based on the microbiome composition and its impact on treatment response in NSCLC.

Asset Subtitle

Anna McLean

Meta Tag

Speaker Anna McLean

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

Endobronchial Ultrasound

EBUS procedure

microbiome samples

non-small cell lung cancer

NSCLC

treatment response

Bronchoalveolar fluid

oral swabs

stool samples

personalized treatment